Novartis, Paratek in deal to develop MRSA drug

10/8/2009 | Reuters

Novartis acquired exclusive global rights to PTK 0796, Paratek Pharmaceuticals' treatment for methicillin-resistant Staphylococcus aureus and other drug-resistant bacteria. The drug is in Phase III trials and has shown promise in safety and tolerability.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA